Phase I Study of HL-085 in Patients With Advanced Solid Tumors
NCT03976050
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
4
Enrollment
INDUSTRY
Sponsor class
Stopped
Study objective and design change
Conditions
Solid Tumor, Adult
Interventions
DRUG:
HL-085
Sponsor
Shanghai Kechow Pharma, Inc.